Japanese Pharmaceutical Market Value Edging Towards $80 Billion by 2020

DALLAS, March 29, 2015 /PRNewswire-iReach/ -- The report "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Japan" is an essential source of information on and analysis of the healthcare, regulatory and reimbursement landscape in Japan. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets.

Photo - http://photos.prnewswire.com/prnh/20150327/194921

Japan's pharmaceutical market value is set to grow at a tepid Compound Annual Growth Rate (CAGR) of 1.3% from $72.8 billion in 2013 to reach $79.8 billion by 2020, driven by new product launches and the healthcare burden of the country's aging population, according to research and consulting firm GlobalData. However, the company's latest report states that the Japanese government's promotion of generic drugs, its biennial pricing review system and the depreciation of the yen against the dollar will be limiting factors in what is the second largest mature pharmaceutical market in the world by value.

The market was valued at $64.2 billion in 2008 and peaked at $88 billion in 2011, before a slight dip to $87.2 billion in 2012. A substantial drop in 2013 saw its value decrease by over $14 billion. In 2013, Japan's population was approximately 127.2 million, having declined at a negative CAGR of 0.02% from 2008. Its public healthcare expenditure accounted for 82.8% of total healthcare expenditure, and the government spent approximately $14 billion on pharmaceutical R&D. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=329874 . (This is a premium report priced at US$3995 for a single user License.)

Deregulation measures introduced in April 2005 have had an impact on overall market performance and more efficient drug reviews have facilitated the entry of new products. The approval process has now caught up with that outside of Japan, as highlighted by two approvals for Bristol-Myers Squibb, the Daklinza (daclatasvir) and Sunvepra (asunaprevir) dual regimen for hepatitis C, and Opdivo (nivolumab) for melanoma, prior to their approval by the US Food and Drug Administration. Aside from wider economic factors, such as currency exchange rates, GlobalData states that increased use of generic drugs will be a key contributor to the forthcoming period of slow growth to 2020.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Japan and includes –

An overview of the pharmaceutical and medical device markets, including market size, segmentation, and key drivers and barriers
Profiles and SWOT analysis of the major players in the pharmaceutical market (Takeda, Otsuka, Pfizer, Astellas and Daiichi Sankyo) and medical device market (Hoya, Siemens Healthcare, Abbott, Medtronic and F. Hoffmann-La Roche)
A review of the reimbursement and regulatory landscape, with analysis covering details of the country's healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices
Detailed analysis of the political and economic environment, covering economic indicators, demographics, healthcare infrastructure and healthcare expenditure
An overview of the opportunities for and challenges to growth in the healthcare market
Reasons to buy

This report will enhance your decision-making capability by allowing you to –

Develop business strategies by understanding the trends shaping and driving Japan's healthcare market
Drive revenue by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to affect Japan's healthcare market
Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investment, and strategic partnerships
Identify, understand, and capitalize on the opportunities and challenges in Japan's healthcare market
Major Points in Table of Contents

3 Overview of the Pharmaceutical and Medical Device Markets
3.1 Pharmaceutical Market
3.1.1 Market Overview
3.1.2 Pharmaceutical Imports and Exports
3.1.3 Supply Channels
3.1.4 Market Segments
3.1.5 Major Therapeutic Areas
3.1.6 Major Players
3.2 Medical Device Market
3.2.1 Market Overview
3.2.2 Overview of Top-Five Segments
3.2.3 Diagnostics Market
3.2.4 Major Players
3.3 Market Drivers and Barriers
3.3.1 Drivers
3.3.2 Barriers
4 Market Access
4.1 Reimbursement and Payer Landscape
4.1.1 Overview of the Healthcare System
4.1.2 Reimbursement Process
4.1.3 Overview of Insurance Providers
4.1.4 Patients' Share of Healthcare Spending
4.1.5 Prescription Drug Price Trend
4.1.6 Pricing Policies
4.2 Regulatory Landscape
4.2.1 Overview
4.2.2 Regulatory Agencies
4.2.3 Market Authorization Procedure for Pharmaceutical Products
4.2.4 New Device Approval Process
4.2.5 Licensing Process for Pharmaceutical and Medical Device Manufacturing
4.2.6 Licensing for Pharmaceutical Exports and Imports
4.2.7 Intellectual Property Rights
4.2.8 Clinical Trial Regulations
4.2.9 Pharmaceutical Advertising Regulations
4.2.10 Pharmacy Regulations
4.2.11 Labeling and Packaging Regulations
5 Country Analysis
5.1 Political Environment
5.1.1 Political Structure
5.1.2 Analysis of Current Political Environment
5.1.3 Healthcare Policy Initiatives
5.2 Economic Landscape
5.3 Economic Indicators
5.3.1 Gross Domestic Product
5.3.2 Gross National Income
5.3.3 Inflation
5.3.4 Currency Exchange Rate
5.3.5 Foreign Direct Investment
5.3.6 Foreign Exchange Reserves
5.3.7 Trade Balance
5.3.8 General Government Structural Balance
5.3.9 General Government Gross Debt
5.3.10 Major Industries
5.4 Demographics
5.4.1 Population
5.4.2 Education and Literacy
5.4.3 Employment
5.4.4 Disease Burden
5.5 Healthcare Infrastructure
5.5.1 Healthcare Facilities
5.5.2 Healthcare Parameters
5.5.3 Environmental Health
5.5.4 Healthcare Personnel
5.6 Healthcare Expenditure
5.6.1 Overview
5.6.2 Major Components of Healthcare Spending
5.6.3 Share of Public and Private Sector
5.6.4 Pharmaceutical and Healthcare R&D Expenditure
5.7 Trade Associations
5.7.1 Japan Pharmaceutical Manufacturers Association
5.7.2 Federation of Pharmaceutical Manufacturers' Associations
5.7.3 Japan Pharmaceutical Traders Association
5.7.4 Japan Pharmaceutical Equipment and Machinery Association
5.8 Trade Fairs
6 Opportunities and Challenges
6.1 Opportunities
6.2 Challenges

Explore more reports on Solar Photovoltaic (PV) at http://www.rnrmarketresearch.com/reports/energy-power/energy/photovoltaics-pv/solar-photovoltaic-pv .

About Us:

RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.

Media Contact: Ritesh Tiwari, RnR Market Research, +1888391544, [email protected]

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE RnRMarketResearch

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.